公司成立于2014年3月10日，于2023年10月16日在全国中小企业股份转让系统挂牌并同步进入创新 层。截至招股说明书签署日，ZHOU ZEQI（周泽奇）直接持有公司34.0923%的股份，并担任公司员工 持股平台丹娜道利和丹娜道和执行事务合伙人，通过丹娜道利和丹娜道和间接合计控制公司5.3542%的 股份，ZHOU ZEQI（周泽奇）直接和间接共控制公司39.4465%的股份，为公司控股股东和实际控制 人。 丹娜生物2025年10月20日披露的招股说明书 显示，公司拟募资13,680.00万元，用于总部基地建设 项目和新产品研发项目。 丹娜生物2025年10月20日披露的向不特定合格投资者公开发行股票并在北京证券交易所上市发行公 告显示，若本次发行成功，预计公司募集资金总额13,680.00万元，扣除发行费用2,223.08万元（不含增 值税）后，预计募集资金净额为11,456.92万元。 保荐机构（主承销商）：招商证券股份有限公司 发行情况： | 股票代码 | 920009 | 股票简称 | 丹娜生物 | | --- | --- | --- | --- | | 申购代码 | 920009 | 上市地点 ...

来源：市场资讯 （来源：国金证券第5小时） | | | 主要财务数据 | | | --- | --- | --- | --- | | | 2024年 | 2023年 | 2022年 | | 营业收入 单位:亿元 | 2.40 | 2.37 | 2.95 | | 净利润 单位:亿元 | 0.87 | 0.78 | 0.45 | | 每股经营活动 产生的现金流量 净额(单位:元) | 2.16 | 1.00 | 1.93 | 产业链上下游 上游:原材料、设备、耗材等 下游:医疗机构等。 o | 申购价格 | 所属行业 | 发行市盈率 | 行业最近一个月平 | | --- | --- | --- | --- | | | | | 均静态市盈率 | | 17.10元 | 医药制造业 | 11.75倍 | 31.59倍 | | 可比公司 | | | | | --- | --- | --- | --- | | 证券简称 | 市盈率(倍) | 市值(亿元) | 近一月涨跌 | | 科美诊断 | 40.93 | 31 | -3.37% | | 亚辉龙 | 52.81 | 82 | -4.22% | 公司主营业务介绍 公司主要从 ...

IPO审核持续提速！根据安排，10月20日—24日这周，沪深北交易所将有健信超导、沐曦股份、双欣环保、爱舍伦4家企业迎来上会大考。伴随上述4家企业 被安排上会，经同花顺iFinD统计，年内安排上会企业数量已达67家，已超去年全年。另外，从当前的IPO存量企业来看，截至目前，共有275家企业正在排 队中，其中北交所存量IPO企业数量居首，达169家，占比超六成。 | 代码 二 > | 公司名称 | 所属行业或领域 | 板块 = | | --- | --- | --- | --- | | A05917.SZ | 内蒙古双欣环保材 ... | 化学原料和化学制品制造业 | 主板 | | A06878.SH | 沐曦集成电路(上 ... | 计算机、通信和其他电子 ... | 科创板 | | A06652.BJ | 江苏爱舍伦医疗科 ... | 医药制造业 | 北证 | | A06726.SH | 宁波健信超导科技 ... | 专用设备制造业 | 科创板 | | A06454.SZ | 深圳天溯计量检测 ... | 专业技术服务业 | 创业板 | | A06721.SH | 北京昂瑞微电子技 ... | 计算机、通信 ...

Core Insights - The overall industrial capacity utilization rate for Q3 2025 is reported at 74.6%, showing a decrease of 0.5 percentage points compared to the same period last year [2] - The mining industry has a capacity utilization rate of 72.5%, down by 2.1 percentage points year-on-year [2] - The manufacturing sector's capacity utilization rate stands at 74.8%, reflecting a decline of 0.4 percentage points from the previous year [3] Industry Breakdown - Mining Industry: Capacity utilization at 72.5%, down 2.1 percentage points from last year [2] - Manufacturing Sector: Capacity utilization at 74.8%, down 0.4 percentage points year-on-year [3] - Electricity, Heat, Gas, and Water Production and Supply: Capacity utilization at 74.3%, unchanged from the previous year [3] Specific Industries - Coal Mining and Washing: 68.9%, down 3.8 percentage points [3] - Food Manufacturing: 70.1%, down 0.6 percentage points [3] - Textile Industry: 77.2%, down 0.7 percentage points [3] - Chemical Raw Materials and Products: 72.5%, down 3.5 percentage points [3] - Non-Metallic Mineral Products: 62.0%, up 0.3 percentage points [3] - Black Metal Smelting and Rolling: 80.1%, up 2.7 percentage points [3] - Non-Ferrous Metal Smelting and Rolling: 77.8%, down 0.6 percentage points [3] - General Equipment Manufacturing: 78.9%, up 0.2 percentage points [3] - Specialized Equipment Manufacturing: 75.5%, down 0.3 percentage points [3] - Automobile Manufacturing: 73.3%, up 0.1 percentage points [3] - Electrical Machinery and Equipment Manufacturing: 74.9%, down 0.7 percentage points [3] - Computer, Communication, and Other Electronic Equipment Manufacturing: 79.0%, up 1.1 percentage points [3]

Core Insights - On October 20, 2023, Boteng Co., Ltd. saw a stock price increase of 2.59% with a trading volume of 336 million yuan [1] - The company reported a financing buy-in amount of 37.97 million yuan and a net financing buy of 642.37 thousand yuan on the same day [1][2] - As of October 20, the total margin balance for Boteng Co., Ltd. was 501 million yuan, representing 3.73% of its market capitalization [1] Financing and Margin Trading - On October 20, the financing buy-in for Boteng Co., Ltd. was 37.97 million yuan, with a current financing balance of 500 million yuan, which is above the 80th percentile of the past year [1] - The company had a margin repayment of 800 shares and a margin sell of 600 shares, with a margin balance of 686.3 thousand yuan, indicating a low level compared to the past year [1] Business Performance - For the first half of 2025, Boteng Co., Ltd. achieved a revenue of 1.621 billion yuan, marking a year-on-year growth of 19.88% [2] - The net profit attributable to shareholders for the same period was 27.06 million yuan, reflecting a significant year-on-year increase of 115.91% [2] Shareholder Information - As of October 10, 2023, the number of shareholders for Boteng Co., Ltd. was 50,100, a decrease of 2.75% from the previous period [2] - The average number of circulating shares per shareholder increased by 2.83% to 9,983 shares [2] Dividend Distribution - Since its A-share listing, Boteng Co., Ltd. has distributed a total of 1.193 billion yuan in dividends, with 866 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 10.7589 million shares, an increase of 2.3886 million shares from the previous period [3] - Tianhong Medical Innovation A was the sixth-largest circulating shareholder, holding 6.398 million shares, a decrease of 513.9 thousand shares [3] - New institutional shareholders included Southern CSI 1000 ETF, which held 3.0218 million shares [3]

IPO and Financing Overview - Four companies are scheduled for IPO review next week (October 20-24), aiming to raise a total of 6.844 billion yuan [1] - Two companies are set for refinancing, with a total planned fundraising of 1.3 billion yuan [5] Company Summaries 1. Jianxin Superconducting Technology Co., Ltd. - The company plans to reduce its fundraising target from 865 million yuan to 775 million yuan, removing the supplementary working capital project [2] - Jianxin focuses on the R&D, production, and sales of core components for MRI equipment, including superconducting magnets, which account for approximately 50% of the cost of MRI equipment [7] - The company has been a pioneer in the mass production of high-field superconducting magnets in China, breaking the long-standing monopoly of foreign manufacturers since 2015 [7] 2. Muxi Integrated Circuit (Shanghai) Co., Ltd. - Muxi specializes in the R&D, design, and sales of high-performance GPU chips and computing platforms, targeting AI training and inference applications [10] - The company has established itself as one of the few in China with comprehensive capabilities in high-performance GPU chip development [10] 3. Shuangxin Environmental Protection Materials Co., Ltd. - Shuangxin is engaged in the R&D, production, and sales of products along the PVA (polyvinyl alcohol) industry chain, including PVA and its specialty fibers [15] - The company has a complete PVA industry chain layout and is controlled by Inner Mongolia Shuangxin Energy Chemical Co., Ltd. [15] 4. Aishalen Medical Technology Group Co., Ltd. - Aishalen focuses on the R&D, production, and sales of disposable medical consumables for rehabilitation and medical protection [19] - The company provides a range of medical dressing products, including medical care pads and surgical gowns [19] Financial Performance Jianxin Superconducting - Total assets as of June 30, 2025, were 688.99 million yuan, with a net profit of 31.92 million yuan for the first half of 2025 [9] - The company has maintained a steady increase in revenue, with a net profit margin of 6.64% [9] Muxi Integrated Circuit - As of March 31, 2025, total assets were approximately 1.046 billion yuan, but the company reported a net loss of 232.51 million yuan for the first quarter of 2025 [12] Shuangxin Environmental Protection - For the first half of 2025, total assets were 623.58 million yuan, with a net profit of 281.08 million yuan [17] - The company has shown a consistent revenue stream, with a net profit margin of 5.95% [17] Aishalen Medical Technology - As of June 30, 2025, total assets were approximately 1.201 billion yuan, with a net profit of 49.43 million yuan [21] - The company has demonstrated a stable growth trajectory, with a net profit margin of 6.61% [21]

【导读】片仔癀三季度净利润下滑近三成 | 行业 | 主营业务收入 | 主营业务成本 | 毛利率(%) | 主营业务收入 | 主营业务成本 | 毛利率增减情况 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 增长率(%) | 增长率(%) | | | 医药制造业 | 401,555.30 | 163,114.02 | 59.38 | -12.93 | 6.81 | 咸少7.51个百分点 | | 医药流通业 | 288,670.85 | 263,743.09 | 8.64 | -8.45 | -4.05 | 咸少4.19个百分点 | | 医药行业合计 | 690,226.15 | 426,857.11 | 38.16 | -11.11 | -0.17 | 咸少6.77个百分点 | | 化妆品业 | 40,012.74 | 15,289.61 | 61.79 | -23.82 | -21.17 | 咸少1.28个百分点 | | 其他 | 11,634.32 | 10,011.73 | 13.95 | -17.28 | -17.86 | 增加0.62个百 ...

针对业绩下降的原因，片仔癀表示，主要原因系年初至报告期末医药制造业销售减少、毛利率下降所 致。 北京商报讯（记者 丁宁）10月17日晚间，片仔癀（600436）发布2025年第三季度报告显示，公司前三 季度营收、净利双降。 财务数据显示，今年前三季度，片仔癀实现的营业收入约为74.42亿元，同比下降11.93%；对应实现的 归属净利润约为21.29亿元，同比下降20.74%；对应实现的扣非净利润约为18.91亿元，同比下降 30.38%。 ...

格隆汇10月17日｜片仔癀(600436.SH)发布2025年第三季度财报显示，营业收入为20.64亿元，同比下降 26.28%，归属于上市公司股东的净利润为6.87亿元，同比下降28.82%。年初至报告期末，公司营业收入 为74.42亿元，同比下降11.93%，归属于上市公司股东的净利润为21.29亿元，同比下降20.74%。业绩减 少主要原因系本报告期医药制造业销售减少、毛利率下降所致。 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-035 二、 公司 2025 年前三季度主营业务分类别情况 单位：万元 人民币 漳州片仔癀药业股份有限公司 2025年前三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露（2022年修订）》《上海证券交易所上市公司行业信息披露指引第六 号——医药制造（2022年修订）》等相关法律法规，漳州片仔癀药业股 份有限公司（以下简称"公司"）现将2025年前三季度主要经营数据披 露如下： 一、 公司 2025 年前三季度主营业务分行业情况 单位：万元 人民币 | 行业 | 主营业务 收入 | 主营业务 成本 | 毛利率 （%） | 主营业务 收入增长 | 主营业务 成本增长 | 毛利率 增减情况 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 率（%） | 率（%） | | | 医药制 造业 | 401,555.30 | 163 ...